AR071696A1 - Vacuna contra leishmania usando un inmunogeno salival de la mosca de la arena. metodos. - Google Patents
Vacuna contra leishmania usando un inmunogeno salival de la mosca de la arena. metodos.Info
- Publication number
- AR071696A1 AR071696A1 ARP090101680A ARP090101680A AR071696A1 AR 071696 A1 AR071696 A1 AR 071696A1 AR P090101680 A ARP090101680 A AR P090101680A AR P090101680 A ARP090101680 A AR P090101680A AR 071696 A1 AR071696 A1 AR 071696A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- seq
- polynucleotide
- vector
- sequence indicated
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 7
- 241000222722 Leishmania <genus> Species 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 title abstract 2
- 239000004576 sand Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 16
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 16
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 16
- 239000002157 polynucleotide Substances 0.000 abstract 14
- 102000040430 polynucleotide Human genes 0.000 abstract 14
- 108091033319 polynucleotide Proteins 0.000 abstract 14
- 239000013598 vector Substances 0.000 abstract 8
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 5
- 239000013604 expression vector Substances 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 239000003085 diluting agent Substances 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 241000701447 unidentified baculovirus Species 0.000 abstract 2
- 239000003981 vehicle Substances 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Insects & Arthropods (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Reivindicacion 1: Una composicion de vacuna, caracterizada porque comprende: a) un vector de expresion, en donde el vector comprende un polinucleotido que codifica uno o m s polipeptidos seleccionados del grupo que consiste de un polipeptido salival de Lu. longipalpis, una variante o fragmento del polipeptido salival de Lu. longipalpis y una mezcla de los mismos; y b) un vehiculo, diluyente o excipiente aceptable para uso en veterinaria o farmaceuticamente aceptable. Reivindicacion 2: La vacuna de la reivindicacion 1, caracterizada porque el vector de expresion se selecciona del grupo que consiste de los vectores pVR2001-TOPO, pVR2001-TOPA, pVR1020, pVR1012, pAB110, ALVAC, TROVAC, MVA y baculovirus. Reivindicacion 5: La vacuna de la reivindicacion 1, caracterizada porque el polinucleotido presenta al menos un 70% de identidad de secuencia con un polinucleotido que tiene la secuencia indicada en la SEQ ID Nø: 2, 4, 6, 8, 12, 14, 16, 18, 21, 22, 89, 90 o 91. Reivindicacion 13: Una composicion de vacuna, caracterizada porque comprende: a) un polipeptido salival de Lu. longipalpis, una variante o un fragmento del polipeptido salival de Lu. longipalpis o una mezcla de los mismos; y b) un veh¡culo, diluyente o excipiente aceptable para uso en veterinaria o farmaceuticamente aceptable. Reivindicacion 15: La vacuna de cualquiera de las reivindicaciones 1-14, caracterizada porque dicha vacuna adem s comprende al menos un ant¡geno de Leishmania. Reivindicacion 18: Un vector, caracterizado porque comprende uno o m s polinucleotidos seleccionados del grupo que consiste de: a) un polinucleotido que codifica un polipeptido que presenta al menos un 80% de identidad de secuencia con un polipeptido que presenta la secuencia indicada en la SEQ ID Nø: 1, 5, 3, 7, 11, 13, 15 o 17; b) un polinucleotido que tiene al menos un 70% de identidad de secuencia con un polinucleotido que codifica un polipeptido que presenta la secuencia indicada en la SEQ ID Nø: 1,3, 5, 7, 11, 13, 15 o 17; y c) un polinucleotido que presenta al menos un 70% de identidad de secuencia con un polinucleotido que tiene la secuencia indicada en la SEQ ID Nø:2, 4, 6, 8, 12, 14, 16, 18, 21, 22, 89, 90 o 91; en donde el vector es un vector de expresion in vivo o un vector de expresion in vitro. Reivindicacion 19: El vector de la reivindicacion 18, caracterizado porque el vector es un vector de baculovirus. Reivindicacion 22: Una celula huesped, caracterizada porque fue transformada con el vector de la reivindicacion 18. Reivindicacion 31: Un polinucleotido aislado, caracterizado porque dicho polinucleotido comprende: a) una secuencia de nucleotidos que presenta al menos un 70% de identidad de secuencia con un polinucleotido que tiene la secuencia indicada en la SEQ ID Nø: 2, 4, 6, 8, 12, 14, 16, 18, 21, 22, 89, 90 o 91; b) una secuencia de nucleotidos que codifica un polipeptido que presenta al menos un 80% de identidad de secuencia con un polipeptido que tiene la secuencia indicada en la SEQ ID Nø: 1, 3, 5, 7, 11, 13, 15 o 17; o c) un polinucleotido que tiene al menos un 70% de identidad de secuencia con un polinucleotido que codifica un polipeptido que presenta la secuencia indicada en la SEQ ID Nø: 1, 3, 5, 7, 11, 13, 15 o 17. Reivindicacion 34: Un polipeptido salival de Lu. longipalpis sustancialmente purificado, caracterizado porque dicho polipeptido comprende: a) una secuencia de amino cidos que presenta al menos un 80% de identidad de secuencia con un polipeptido que tiene la secuencia indicada en la SEQ ID Nø: 1, 5, 3, 7, 11, 13,15 o 17; b) una variante conservadora de la secuencia de amino cidos indicada en la SEQ ID Nø: 1, 5, 3, 7, 11, 13, 15 o 17; c) un fragmento inmunogenico que comprende al menos ocho amino cidos consecutivos de la secuencia de amino cidos indicada en la SEQ ID Nø: 1, 3, 5, 7, 11, 13, 15 o 17, que se une espec¡ficamente a un anticuerpo que se une espec¡ficamente a la secuencia de amino cidos indicada en la SEQ ID Nø: 1, 3, 5, 7, 11, 13, 15 o 17; o d) una secuencie de amino cidos indicada en la SEQ ID Nø: 1, 3, 5, 7, 11, 13, 15 o 17, y en donde administracion del polipeptido a un sujeto produce una respuesta inmune contra Lu. longipalpis. Reivindicacion 37: Un anticuerpo, caracterizado porque se une espec¡ficamente al polipeptido de la reivindicacion 34.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5163508P | 2008-05-08 | 2008-05-08 | |
| US10134508P | 2008-09-30 | 2008-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071696A1 true AR071696A1 (es) | 2010-07-07 |
Family
ID=41110966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101680A AR071696A1 (es) | 2008-05-08 | 2009-05-08 | Vacuna contra leishmania usando un inmunogeno salival de la mosca de la arena. metodos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8603808B2 (es) |
| EP (2) | EP2899203B1 (es) |
| CN (2) | CN103768588A (es) |
| AR (1) | AR071696A1 (es) |
| BR (1) | BRPI0915605B8 (es) |
| ES (1) | ES2760004T3 (es) |
| HK (1) | HK1150616A1 (es) |
| IL (1) | IL209107A (es) |
| MA (1) | MA32376B1 (es) |
| MX (2) | MX2010012069A (es) |
| WO (1) | WO2009137577A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103768588A (zh) * | 2008-05-08 | 2014-05-07 | 梅里亚有限公司 | 使用白蛉唾液免疫原的利什曼原虫疫苗 |
| CN104717976A (zh) | 2012-08-30 | 2015-06-17 | 梅里亚有限公司 | 嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法 |
| EP2935581A4 (en) * | 2012-12-21 | 2016-07-27 | Merck Sharp & Dohme | EXPRESSION VECTORS FOR THE PRODUCTION OF RECOMBINANT PROTEINS IN MAMMALIAN CELLS |
| MX2017005687A (es) | 2014-11-03 | 2017-08-21 | Merial Inc | Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia. |
| AR111842A1 (es) | 2017-06-02 | 2019-08-21 | Amgen Inc | Antagonistas de péptido pac1 |
| CN113337542A (zh) * | 2021-06-10 | 2021-09-03 | 山西大学 | 高效表达利什曼原虫pepck的人复制缺陷型重组腺病毒载体 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4963481A (en) | 1985-12-18 | 1990-10-16 | Genetics Institute Inc | Promoter system |
| DK175363B1 (da) | 1986-09-12 | 2004-09-13 | Genentech Inc | Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren |
| IL84154A0 (en) | 1986-10-16 | 1988-03-31 | Microgenesys Inc | Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| DE3743138A1 (de) | 1987-12-18 | 1989-09-14 | Mayr Christian Gmbh & Co Kg | Schleifringlose, elektromagnetische ueberlastkupplung |
| CA2003300A1 (en) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
| US6780407B1 (en) | 1989-03-08 | 2004-08-24 | Aventis Pasteur | Pox virus comprising DNA sequences encoding CEA and B7 antigen |
| US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
| KR100242671B1 (ko) | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
| US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| FR2712603B1 (fr) | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Virus recombinants, préparation et utilisation en thérapie génique. |
| US5529780A (en) | 1994-03-30 | 1996-06-25 | Virogenetics Corporation | Nucleotide and amino acid sequences of canine herpesvirus gB and gC |
| EP0826063A1 (en) | 1995-04-25 | 1998-03-04 | Vical Incorporated | Single-vial formulations of dna/lipid complexes |
| EP0803573A1 (en) | 1996-04-25 | 1997-10-29 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Polycistronic expression construct with cytokines for multivalent vaccines |
| US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
| FR2750865B1 (fr) | 1996-06-27 | 1998-12-04 | Rhone Merieux | Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2 |
| US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
| US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
| WO1998000166A1 (en) | 1996-07-03 | 1998-01-08 | Merial, Inc. | Recombinant canine adenovirus (cav) containing exogenous dna |
| FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
| FR2776928B1 (fr) | 1998-04-03 | 2000-06-23 | Merial Sas | Vaccins adn adjuves |
| TWI224107B (en) | 1998-10-22 | 2004-11-21 | Pfizer Prod Inc | Novel proteins from actinobacillus pleuropneumoniae |
| US6017537A (en) | 1998-12-18 | 2000-01-25 | Connaught Laboratories, Inc. | Formyl methionyl peptide vaccine adjuvant |
| US6645740B1 (en) | 1999-06-10 | 2003-11-11 | Merial Limited | Nucleic acids encodings equine GM-CSF |
| FR2796397B1 (fr) | 1999-07-16 | 2006-09-01 | Merial Sas | Genes de calicivirus felin et vaccins notamment vaccins recombines |
| AP1775A (en) | 1999-09-25 | 2007-08-28 | Univ Iowa Res Found | Immunostimulatory nucleic acids. |
| US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
| EP1203819A3 (en) | 2000-10-06 | 2002-08-07 | Transgene S.A. | Anti-inflammatory vectors |
| BR0210539A (pt) * | 2001-06-19 | 2005-04-26 | Us Gov Health & Human Serv | Processos de seleção e uso de vacinas de vetor antiartrópode |
| FR2829498B1 (fr) | 2001-09-11 | 2003-11-28 | Merial Sas | Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins |
| WO2003062374A2 (en) | 2001-11-09 | 2003-07-31 | Entremed, Inc. | Synthetic genes for malarial proteins and methods of use |
| WO2004024027A2 (en) | 2002-06-07 | 2004-03-25 | University Of Florida | Endodontic files made using bulk metallic glasses |
| EP1572968B1 (en) * | 2002-10-29 | 2009-04-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Lutzomyia longipalpis polypeptides and methods of use |
| WO2005039633A1 (de) * | 2003-10-24 | 2005-05-06 | Mologen Ag | Mittel zur behandlung von infektionen mit leishmanien |
| US7582302B2 (en) | 2004-06-04 | 2009-09-01 | Merial Limited | Needle-free administration of FeLV vaccines |
| US7512883B2 (en) * | 2004-06-30 | 2009-03-31 | Microsoft Corporation | Portable solution for automatic camera management |
| CA2540736A1 (en) * | 2005-04-08 | 2006-10-08 | Institut Pasteur | Polypeptides of leishmania major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof |
| CA2670097C (en) * | 2006-11-21 | 2015-10-06 | Merial Limited | Prime boost canine leishmania vaccine |
| WO2009017689A2 (en) * | 2007-08-02 | 2009-02-05 | Government Of The U. S. A., As Represented By The Secretary, Dept. Of Health And Human Services | Methods for detection and prevention of tick infestation and pathogen transmission |
| CN103768588A (zh) * | 2008-05-08 | 2014-05-07 | 梅里亚有限公司 | 使用白蛉唾液免疫原的利什曼原虫疫苗 |
| AR073170A1 (es) * | 2008-05-21 | 2010-10-20 | Infectious Disease Res Inst | Vacunas de poliproteinas recombinantes para el tratamiento y diagnostico de leishmaniasis |
| US8410258B2 (en) * | 2008-05-21 | 2013-04-02 | Infections Disease Research Institute | Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis |
| WO2010078469A2 (en) * | 2008-12-31 | 2010-07-08 | The Usa As Represented By The Secretary, Department Of Health And Human Services | Sand fly salivary proteins as novel factor xa inhibitors and methods of use |
| WO2010078466A2 (en) * | 2008-12-31 | 2010-07-08 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Sand fly salivary proteins with anti-complement activity and methods of their use |
| EP2621527A4 (en) * | 2010-10-01 | 2015-12-09 | Univ Pennsylvania | USE OF LISTERIA VACCINE VECTORS TO REVERSE VACCINE IMMUNITY IN PATIENTS WITH PARASITIC INFECTIONS |
| MX350099B (es) * | 2010-11-18 | 2017-08-25 | Us Gov Health & Human Services | Modelo de estimulación canino para leishmania mediante picaduras de moscas de arena. |
| BR112014001086A2 (pt) * | 2011-07-21 | 2017-02-21 | Consejo Superior De Investig Cientificas/Csic | molécula quimérica útil na imunoterapia contra a leishmaniose, a qual compreende um fragmento da proteína pfr1 de leishmania infantum com epítopos específicos imunodominantes |
| AU2013235423B2 (en) * | 2012-03-20 | 2017-03-30 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein C and uses thereof |
-
2009
- 2009-05-06 CN CN201410067819.XA patent/CN103768588A/zh active Pending
- 2009-05-06 BR BRPI0915605-4 patent/BRPI0915605B8/pt active IP Right Grant
- 2009-05-06 CN CN2009801236269A patent/CN102066411A/zh active Pending
- 2009-05-06 EP EP15154516.7A patent/EP2899203B1/en active Active
- 2009-05-06 US US12/436,398 patent/US8603808B2/en active Active
- 2009-05-06 ES ES15154516T patent/ES2760004T3/es active Active
- 2009-05-06 MX MX2010012069A patent/MX2010012069A/es active IP Right Grant
- 2009-05-06 WO PCT/US2009/042980 patent/WO2009137577A2/en active Application Filing
- 2009-05-06 EP EP09743563.0A patent/EP2283035B1/en active Active
- 2009-05-06 MX MX2014013606A patent/MX348137B/es unknown
- 2009-05-08 AR ARP090101680A patent/AR071696A1/es active IP Right Grant
-
2010
- 2010-11-04 IL IL209107A patent/IL209107A/en active IP Right Grant
- 2010-12-03 MA MA33392A patent/MA32376B1/fr unknown
-
2011
- 2011-05-13 HK HK11104707.3A patent/HK1150616A1/zh unknown
-
2013
- 2013-11-01 US US14/069,406 patent/US9228002B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8603808B2 (en) | 2013-12-10 |
| HK1150616A1 (zh) | 2012-01-06 |
| ES2760004T3 (es) | 2020-05-12 |
| US9228002B2 (en) | 2016-01-05 |
| WO2009137577A2 (en) | 2009-11-12 |
| EP2899203A3 (en) | 2015-08-05 |
| IL209107A0 (en) | 2011-01-31 |
| IL209107A (en) | 2017-08-31 |
| EP2899203A2 (en) | 2015-07-29 |
| EP2283035A2 (en) | 2011-02-16 |
| CN103768588A (zh) | 2014-05-07 |
| BRPI0915605A2 (pt) | 2016-02-02 |
| US20090324649A1 (en) | 2009-12-31 |
| MA32376B1 (fr) | 2011-06-01 |
| MX348137B (es) | 2017-05-29 |
| CN102066411A (zh) | 2011-05-18 |
| BRPI0915605B1 (pt) | 2021-08-24 |
| BRPI0915605B8 (pt) | 2021-09-08 |
| US20140294875A1 (en) | 2014-10-02 |
| MX2010012069A (es) | 2010-12-14 |
| EP2899203B1 (en) | 2019-07-10 |
| WO2009137577A3 (en) | 2010-03-25 |
| EP2283035B1 (en) | 2015-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071696A1 (es) | Vacuna contra leishmania usando un inmunogeno salival de la mosca de la arena. metodos. | |
| HRP20140109T1 (hr) | Novi imunoadjuvantni spojevi na bazi flagelina i njihova upotreba | |
| HRP20160798T1 (hr) | Rekombinantni antigeni iz rsv | |
| DOP2021000197A (es) | Composición farmacéutica, que comprende la variante de hialuronidasa ph20 humana y fármaco, para inyección subcutánea | |
| AR110502A1 (es) | Polinucleótidos y polipéptidos de adenovirus | |
| CL2019003406A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
| JP2018510215A5 (es) | ||
| PE20210376A1 (es) | Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer | |
| PE20171111A1 (es) | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso | |
| JP2012501959A5 (es) | ||
| EP2532366A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| JP2015214545A5 (es) | ||
| PE20161560A1 (es) | Vacuna de pcsk9 | |
| AR036160A1 (es) | Regulacion de las vias metabolicas lipidicas en las plantas, mediante transgenesis con sentido o antisentido de factores de transcripcion hap2, hap5 y hap3/lec1 | |
| AR078085A1 (es) | Peptidos tau antigenicos y usos de los mismos | |
| EA200870237A1 (ru) | Последовательности пептидов и композиции | |
| JP2012102105A5 (es) | ||
| ES2531115T3 (es) | Combinaciones de clados de RrgB neumocócicos | |
| AR105482A1 (es) | Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso | |
| AR085167A1 (es) | Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit | |
| RU2010154101A (ru) | Пептиды эпитопов mybl2 и содержащие их вакцины | |
| AR075933A1 (es) | Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso | |
| DE602005015368D1 (de) | Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen | |
| AR074273A1 (es) | Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo | |
| AR080621A1 (es) | Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una enfermedad parasitaria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |